Protagonist TherapeuticsPTGX
About: Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Employees: 125
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 8 (+2) [Q2]
14% more capital invested
Capital invested by funds: $1.79B [Q1] → $2.05B (+$258M) [Q2]
1% more funds holding
Funds holding: 184 [Q1] → 186 (+2) [Q2]
7% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 27
9% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 68
5.41% less ownership
Funds ownership: 106.06% [Q1] → 100.65% (-5.41%) [Q2]
87% less call options, than puts
Call options by funds: $956K | Put options by funds: $7.56M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
TD Cowen Tara Bancroft 67% 1-year accuracy 2 / 3 met price target | 41%upside $65 | Buy Initiated | 24 Sept 2024 |
HC Wainwright & Co. Douglas Tsao 60% 1-year accuracy 74 / 123 met price target | 9%upside $50 | Buy Maintained | 12 Sept 2024 |
Truist Securities Srikripa Devarakonda 63% 1-year accuracy 10 / 16 met price target | 31%upside $60 | Buy Initiated | 9 Sept 2024 |
JMP Securities Jonathan Wolleben 47% 1-year accuracy 34 / 72 met price target | 6%downside $43 | Market Outperform Maintained | 7 Aug 2024 |
HC Wainwright & Co. Douglas Tsao 60% 1-year accuracy 74 / 123 met price target | 13%downside $40 | Buy Maintained | 7 Aug 2024 |
